Skip to main content

An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Trial Status: Closed to Accrual

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are advanced or have spread.

Inclusion Criteria

  • Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Must have received and progressed on or failed one standard/approved treatment for cancer type, if available
  • At least 4 weeks since any previous treatment for cancer
  • Subject must consent to pretreatment and on treatment tumor biopsies
  • At least one lesion with measurable disease at baseline
  • Adequate organ and marrow function

Exclusion Criteria

  • Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
  • Prior organ transplant
  • Participants with second/other active cancers requiring current treatment
  • Uncontrolled/significant heart disease
  • History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
  • Active/uncontrolled autoimmune disease
  • Active infection

New Jersey

Hackensack University Medical Center
Status: ACTIVE

New York

New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center


Fox Chase Cancer Center
Status: ACTIVE
University of Pennsylvania / Abramson Cancer Center
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE


Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA020-002
  • Secondary IDs NCI-2017-00261, 2016-002263-34
  • ID NCT02913313